The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Sovaldi™ (sofosbuvir) and Hepatitis C

What is Sovaldi™ (sofosbuvir)?

On December 6, 2013, the U.S. Food and Drug Administration approved the prescription medication Sovaldi™ (sofosbuvir) as a component in a combination antiviral treatment regimen to treat chronic Hepatitis C infection, genotype 1, 2, 3, or 4, including those with hepatocellular carcinoma meeting Milan criteria (awaiting liver transplant) and those co-infected with Hepatitis C and HIV.

Sovaldi™ is a prescription once-daily oral nucleotide analog polymerase inhibitor to be used in combination with peginterferon alfa and ribavirin OR ribavirin. The active ingredient in this 400 mg tablet is sofosbuvir.

Last Updated: July 2014

"Full Prescribing Information." Gilead.com. Gilead Sciences, Inc., http://www.gilead.com/~/media/Files/pdfs/medicines/liver-disease/sovaldi/sovaldi_pi.pdf. Retrieved December 31, 2013.

"Patient Information: Sovaldi™." Gilead.com. Gilead Sciences, Inc., http://www.gilead.com/~/media/Files/pdfs/medicines/liver-disease/sovaldi/sovaldi_patient_pi.pdf. Retrieved December 31, 2013.

"Register for a SOVALDI Co-pay Coupon." Sovaldi.com. Gilead Sciences, Inc., https://www.sovaldi.com/copay-register.aspx. Retrieved December 31, 2013.

"Support Path." MySupportPath.com. Gilead Sciences, Inc., http://www.mysupportpath.com/. Retrieved December 31, 2013.

"U.S. Food and Drug Administration Approved Gilead's Sovaldi (Sofosbuvir) for the Treatment of Chronic Hepatitis C." Gilead.com. Gilead Sciences, Inc., http://investors.gilead.com/phoenix.zhtml?c=69964&p=irol-newsArticle&ID=1882800&highlight=. Retrieved December 31, 2013.